Cytokinetics EVP exercises 2,295 options, sells 2,295 shares

Cytokinetics (CYTK) reported an insider transaction by its EVP, Research & Development.

Rhea-AI Filing Summary

Cytokinetics (CYTK) reported an insider transaction by its EVP, Research & Development. On 11/04/2025, the officer exercised 2,295 incentive stock options at $10.60 per share (code M) and sold 2,295 common shares at $59.55 (code S). Following these transactions, the officer held 140,610 common shares directly and retained 6,600 derivative securities (options).

Insights

Insider transactions & governance analyst

Routine option exercise and same-day sale; limited broader impact.

The EVP, Research & Development executed a standard Form 4 sequence: code M reflects exercising $10.60 options for 2,295 shares, followed by a code S sale of the same 2,295 shares at $59.55 on 11/04/2025. This is a common administrative event when options approach or are within their exercisable window.

Post-transaction, direct ownership stands at 140,610 common shares, with 6,600 derivative securities remaining. The filing lists both transactions clearly; actual market impact depends on overall float and liquidity, which are not provided in the excerpt.

Insider Trade Summary

Exercise and Sale: 2,295 shares ($112K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 2,295 shs ($137K)

Approx. gross sale proceeds $137K

Approx. exercise cost $24K

Approx. pre-tax spread $112K

Type	Security	Shares	Price	Value
Exercise	Incentive Stock Option (Right to Buy)	2,295	$0.00	$0.00
Exercise	Common Stock	2,295	$10.60	$24K
Sale	Common Stock	2,295	$59.55	$137K

Holdings After Transaction: Incentive Stock Option (Right to Buy) — 6,600 contracts (Direct); Common Stock — 140,610 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTK report on this Form 4?

An officer exercised 2,295 options at $10.60 and sold 2,295 common shares at $59.55 on 11/04/2025.

Who is the reporting person in the CYTK Form 4?

The reporting person is the EVP, Research & Development.

How many CYTK shares does the officer own after the transaction?

Direct beneficial ownership is 140,610 common shares after the reported transactions.

What derivative securities remain after the CYTK Form 4 transactions?

The officer retains 6,600 derivative securities (incentive stock options).

What do the Form 4 transaction codes M and S mean for CYTK?

M indicates an option exercise; S indicates an open market or private sale of common stock.

What were the exact prices involved in the CYTK transactions?

Options were exercised at $10.60 per share and shares were sold at $59.55 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/04/2025 - 07:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/04/2025		M		2,295	A	$10.6	142,905	D
Common Stock	11/04/2025		S		2,295	D	$59.55	140,610	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (Right to Buy)	$10.6	11/04/2025		M			2,295	03/28/2017	02/28/2027	Common Stock	2,295	$0	6,600	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	11/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.